Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30201378 | 0.89 | OPRK1 (0.61) | OPRK1MEN1KMT2A | |
| SCHEMBL30201412 | 0.88 | CXCR6 (0.55) | OPRK1MEN1KMT2A | |
| SCHEMBL30201472 | 0.87 | MEN1 (0.52) | MEN1KMT2A | |
| SCHEMBL30201364 | 0.87 | MEN1 (0.64) | OPRK1MEN1KMT2A | |
| SCHEMBL30201517 | 0.86 | SMYD3 (0.52) | OPRK1 | |
| SCHEMBL30201262 | 0.80 | MEN1 (0.61) | OPRK1MEN1KMT2A | |
| SCHEMBL30201509 | 0.80 | DRD4 (0.55) | DRD4MEN1KMT2A | |
| SCHEMBL24950984 | 0.80 | MAPT (0.58) | MEN1KMT2A | |
| SCHEMBL30201525 | 0.80 | MAPT (0.58) | MEN1KMT2A | |
| SCHEMBL24950982 | 0.77 | SMYD3 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4376818-B1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC (US) | 2025-06-18 | — | — | EP | claimed |
| US-12209084-B2 | Serotonin 5-HT2B inhibitory compounds | ZOETIS SERVICES LLC (US) | 2025-01-28 | — | — | US | claimed |
| WO-2023009330-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC (US) | 2023-02-02 | — | — | WO | claimed |
| CN-117729914-A | Serotonin 5-HT2B inhibiting compounds | 硕腾服务有限责任公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2023009330-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209084-B2 | Serotonin 5-HT2B inhibitory compounds | HTR2B, HTR1B, HTR1A | DRD4 148/4885OPRK1 928/4885MEN1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.